Australia’s pot industry is at an earlier stage compared to that of Canada, wherein the medicinal use is restricted but legal with recreational use remaining illegal. In a bid to dominate a global market that’s set to be worth US$55 billion by 2025, Australia legalized exports of medicinal cannabis this year. The ASX’s range now include over 20 pot stocks companies. Here are 6 of those stocks.
ALTHEA GROUP HOLDINGS LIMITED (ASX: AGH) – The company has achieved the first stage of its business plan, after the generation of sales revenue from May 2018. For the financial period, the loss of the company after providing for tax amounted $1,871,585. No dividends were paid or declared since the start of the financial period. As at the end of financial year, the cash at bank was of $2,300,335 with no significant debt. The proceeds from the funds raised through an IPO will be used to increase brand awareness for its medicinal cannabis products. Althea signs distribution agreement with major independent cannabis distributor, Health House International. The stock has traded flat as at October 22, 2018, to trade at a market price of $0.495. In the last 5 days the stock has seen a performance change of -11.61%.
BOD AUSTRALIA LIMITED (ASX: BDA) – During FY2018, Bod significantly strengthened its revenue profile, Revenue for the period was $1,170,206, which represents a 231% increase on the previous corresponding period FY2017 of $352,877. This is due to increase in the Company’s distribution network, ongoing marketing and branding initiatives and additions to the product range. The loss for the company after providing for income tax amounted to $3,672,105 and hence there were no dividends paid, recommended or declared during the current or previous financial year. The stock fell -1.639% as at October 22, 2018, to trade at a market price of $0.600. In the last one year the stock has seen a performance change of 522.45% and an overall performance of positive 110.34%.
BOTANIX PHARMACEUTICALS LTD (ASX: BOT) – A dermal delivery device allowing 10 to 20 times more of the active ingredient to get through the skin, the company has also licensed a novel transdermal drug delivery technology called PermetrexTM. The net loss attributable to members of the company for the year ended 30 June 2018 is $11,011,813 compared to 30 June 2017 of $4,773,098. BOT had a net working capital surplus of $16,284,891 at 30 June 2018 compared to 30 June 2017 of $5,436,823. As at 30 June 2018 the group had a cash balance of $17,263,408 compared to 30 June 2017 of $5,720,514. The stock has traded flat as at October 22, 2018, to trade at a market price of $0.089. In the last one year the stock has seen a performance change of 102.27%.
CANN GROUP LIMITED (ASX: CAN) – The company reported after 82.61% rise in net loss in FY 18 as on September 21, 2018. However, at a price of $2.50 per share in FY 18 the company has raised funds of approximately $78 million. At the end of FY 19, it is expected that the construction on the Phase 3 expansion facility will be well underway. The revenue for 2018 has been positive at $560,000. Cann has established a strong record of meeting the standards required in securing regulatory approvals. However, no dividends have been paid or have been recommended during the year on account of an overall loss. The stock fell 0.733% as at October 22, 2018, to trade at a market price of $2.710. In the last one year the stock has seen a performance change of 93.62%.
ELIXINOL GLOBAL LIMITED (ASX: EXL) – To provide working capital the company is investing cash in the Japanese market for hemp-derived CBD, foods and skincare, to enhance the business for expected growth. The company reported a maiden profit of $0.6m and record revenues of $14.9m reported in 1H FY2018. Also, raised $40m in October 2018 to accelerate international growth. Through a mix of organic and acquisitive growth seeking global market leading position. As at October 2018 company has A$ 54.2 million cash at bank with minimum debt of A$0.25 million. The P/E of the stock is 1,575 (quite high) and the earnings per share (EPS) is of 0.001AUD which is better than the peer basket. The stock fell 6.349% as at October 22, 2018, to trade at a market price of $1.770. In the last six months the stock has seen a performance change of 8.62%.
ESENSE-LAB LTD (ASX: ESE) – The company posted revenue from continuing operations has decreased to USD $11,000 as at June 30, 2018 from USD $53,000 as at June 30, 2017. Net Loss increased from $1,159,000 in 2017 to $1,192,000 in 2018 for the period attributable to members. For the current year no dividend was declared, recommended and paid or was paid for the previous year. At the end of the financial year period the cash and cash equivalents decreased from $1,907,000 in 2017 to $951,000 in 2018. The Directors comment when and if dividends will be paid in the future as the payment of any dividends will depend on the financial position, future profitability, and cash requirements of the Company. The stock fell 10% as at October 22, 2018, to trade at a market price of $0.063. In the last one year the stock has seen a performance change of -72.55%.
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a company’s prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.